期刊文献+

208例银屑病的临床分析

Clinical analysis of 208 psoriasis cases.
下载PDF
导出
摘要 目的分析总结昆明地区银屑病患者在病因、临床表现、治疗等方面的情况,以提高临床诊疗水平。方法回顾性调查并分析2002~2003年昆明地区208例银屑病患者的各项临床情况。结果遗传、感染、药物等因素在寻常型银屑病的发病中作用较大,脓疱型及红皮症型的发病多与治疗不当有关;外用新型的皮质类固醇及维甲酸类制剂可取得较好的治疗效果。结论银屑病的临床表现多样,病因复杂,可能存在着地区差异,新一代药物的治疗前景广阔。 Objective To analyse the etiological factor, clinical situation and therapeutics of psoriasis in Kunming area and to promote the clinical level of diagnosis and therapy. Methods Retrospective studies was used to analyse the various situation of 208 patients with psoriasis in Kunming area from the year of 2002 to 2003. Results Some factors such as inheritance and infection and drug and so on play an important role in the onset of psoriasis vulgaris, and maybe incorrect therapy is the main agent to induce the appearance of psoriasis pustulosa and erythroderma psoriaticum, also, topical application of some new type of corticosteroid and retinoic acid is more effective than the old type. Conclusion Psoriasis has diverse clinical features and complicated etiology, and maybe there are some difference between different areas, and, the prospect of the new generation of drug for the treatment of psoriasis is hopeful.
出处 《中国热带医学》 CAS 2005年第3期511-512,共2页 China Tropical Medicine
关键词 银屑病 昆明地区 皮质类固醇 脓疱型 Psoriasis Clinical analysis Kunming City
  • 相关文献

参考文献7

二级参考文献45

  • 1李志刚 李玉琳.复方青黛饮治疗银屑病150例报告[J].中国皮肤性病学杂志,1992,6:52-52.
  • 2[5]Chaudhari U, Romano P, Mulcahy LD,et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised tril[J]. Lancet,2001,357(9271 ): 1842~1847.
  • 3[6]Mease PJ, Goffe BS,Metz J,et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial[J]. Lancet, 2000,356 (9227): 385~390.
  • 4[7]Bachelez H, Flageul B, Dubertret L, et al. Treatment of recalcitrant plaque psoriasis with a humanized non-depleting antibody to CD4[J]. J Autoimmun, 1998,11 (1): 53~62.
  • 5[8]Krueger JG, Walters IB, Miyazawa M, et al. Successful in vivo blockade of CD25(high-affinity interleukin 2 receptor)on Tcells by administration of humanized anti-Tac antibody to patients with psoriasis[J] .J Am Acad Dermatol, 2000,43 (3): 448~458.
  • 6[9]Gottlieb A, Krueger JG, Bright R,et al. Effects of administration of a single dose of a humanized monoclonal antibody to CDlla on the immunobiology and clinical activity of psoriasis[J]. J Am Acad Dermatol, 2000,42(3):428~443.
  • 7[10]Martin A, Gutierrez E, Muglia J, et al. A multicenter doseescalation trial with denileukin diftitox(ONTAK, DAB (389) IL-2) in patients with severe psoriasis[J]. J Am Acad Dermatol,2001,45(6) :871~881.
  • 8[11]Ellis CN, Krunger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes[J]. N Engl J Med, 2001,345(4) :248~255.
  • 9[12]Ogata A, Nishimoto N, Yoshizaki K. Advances in interleukin-6 therapy. Rinsho Byori[J]. 1999,47(4) :321~326.
  • 10[13]Hong K, Chu A, Ludviksson BR, et al. IL-12, independently of IFNgamma,plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder[J] .J Immunol, 1999,162(12) :7480~7491.

共引文献85

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部